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Objectives We sought to evaluate differences in late safety outcomes relative to dual antiplatelet
therapy (DAPT) duration in patients treated with zotarolimus-eluting stents (ZES).
Background Despite treatment recommendations for at least 12 months of DAPT following drug-
eluting stent revascularization, device-speciﬁc outcomes relative to DAPT duration are absent.
Methods Among 2,032 patients undergoing percutaneous coronary revascularization with ZES in
5 trials, late safety events were compared relative to DAPT duration for patients with 6 months
DAPT adherence and survival free of major ischemic and bleeding events.
Results A total of 1,414 event-free patients on DAPT at 6 months were identiﬁed. Patient group
comparisons relative to DAPT included: 6 months versus 12 months, and 6 months versus 24
months. Through 3 years, risk-adjusted ischemic event rates did not signiﬁcantly differ between
groups: 6 versus 12 months: death (2.7% vs. 2.2%), myocardial infarction (MI, 0.3% vs. 1.1%), and
deﬁnite/probable stent thrombosis (ST, 0.3% vs. 0%); 6 versus 24 months: death (1.6% vs. 1.6%),
MI (0.4% vs. 1.2%), and deﬁnite/probable ST (0.1% vs. 0.2%). Composite events also did not statisti-
cally vary between DAPT durations. In multivariable analysis, 6-month versus longer DAPT duration
was not associated with increased likelihood of thrombotic events at 3-year follow-up. Major bleed-
ing was negligible across groups.
Conclusions Among patients treated with ZES, late-term events of death, MI, stroke, and ST do not
signiﬁcantly differ between patients taking 6 months DAPT compared with continuation beyond 1
year. These ﬁndings merit further study to identify the appropriate duration of DAPT according to
speciﬁc drug-eluting stents. (J Am Coll Cardiol Intv 2011;4:1119–28) © 2011 by the American
College of Cardiology Foundation
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1120An important focus of investigation for drug-eluting stents
(DES) has been whether late adverse ischemic events, in
particular stent thrombosis (ST), may be attenuated through
extended prescription of dual antiplatelet therapy (DAPT)
beyond that described in product labeling (1–3). Following
review of evidence indicating a numerical excess of late ST
with sirolimus- and paclitaxel-eluting coronary stents (4,5),
U.S. Food and Drug Administration treatment guidelines
See page 1129
advocated 12-month therapy with aspirin and a thienopyri-
dine following DES placement and in the absence of
contraindications (2,6,7). Importantly, however, this recom-
mendation for instructing clinical practice was based empir-
ically on consensus opinion and prior studies indicating that
long-term DAPT may confer a lower risk of death and
myocardial infarction (MI) rather than on any available
evidence associating extended DAPT duration with a re-
duction in late ST (3,8,9).
At present, studies examining the relationship between
DAPT and outcomes following
revascularization with DES have
been limited by trial design or
methods that have restricted
their applicability to clinical de-
cision making in routine prac-
tice. Although observational
studies have consistently associ-
ated premature discontinuation
of DAPT with a higher risk of
ST (10–13), additional studies
have demonstrated that long-
term DAPT may be associated with reductions in death and
MI, but may not influence ST events (2,3). In addition, few
studies have formally evaluated compliance or bleeding risks
associated with long-term DAPT. Accordingly, identifica-
tion of the “optimal” duration of DAPT has been associated
with several challenges and uncertainties (14).
Whether differences in late safety outcomes exist accord-
ing to duration of DAPT and are specific to DES type is
also not well understood. To this purpose, we examined
intermediate-term and late safety outcomes, including ischemic
and bleeding events, relative to the duration of DAPT
compliance across 5 registration trials involving patients
treated with zotarolimus-eluting stents (ZES) (Endeavor
stent, Medtronic Inc., Santa Rosa, California).
Methods
Overview of trials and study population. The Endeavor
tent clinical trials program constitutes a series of prospec-
ive, international trials enrolling patients with symptomatic
Abbreviations
and Acronyms
CK  creatine kinase
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
MI  myocardial infarction
ST  stent thrombosis
ZES  zotarolimus-eluting
stent(s)schemic heart disease as a result of de novo stenotic lesions50% angiographic diameter stenosis by visual estimate) in
ative coronary arteries (15–19). In all trials, patients were
xcluded if they experienced recent (72 h) MI, underwent
rior stent placement within the target vessel or any other
essel within 30 days of the index procedure, or had any
eneral contraindication to the revascularization procedure
nd routine pharmacological therapies. Principal angio-
raphic exclusion criteria were a left ventricular ejection
raction30%, stenosis40% elsewhere in the target vessel
other than the target lesion), involvement of a side branch
2.0 mm in diameter, unprotected left main coronary
isease, total occlusions, and Thrombolysis In Myocardial
nfarction flow grade 2 in the treatment vessel. The
tudies were approved by the institutional review board or
thics committee at each enrolling site, and consecutive,
ligible patients signed written informed consent before the
nterventional procedure.
This analysis was limited to patients enrolled in these
rials who were treated with the Endeavor stent (ZES)
Medtronic Inc.), a cobalt-based alloy stent with a phos-
horylcholine polymer and zotarolimus dose concentration
f 10 g/mm stent length. Depending upon the trial, ZES
were available in diameters ranging from a minimum of 2.25
mm to a maximum of 3.5 mm and in lengths from 9 to 30
mm. Before revascularization, all patients received treat-
ment with aspirin (325 mg/day) and clopidogrel (75 mg/
day) for at least 48 h, or alternatively, a loading dose of
clopidogrel (300 to 600 mg) was given immediately
before or during the procedure. Per protocol, all patients
were treated with a minimum of 3 months of DAPT
except for the ENDEAVOR IV (Randomized, Controlled
Trial of the Medtronic Endeavor Drug [Abt-578] Eluting
Coronary Stent System Versus the TaxusTM Paclitaxel-
Eluting Coronary Stent System in De Novo Native Coro-
nary Artery Lesions) trial, in which patients received a
minimum 6 months of DAPT to maintain blinding of DES
assignment with the comparator paclitaxel-eluting stent.
Aspirin therapy was recommended for an indefinite time.
Adherence to thienopyridine therapy was monitored at
30 days, 6 months, and then annually through 3 years. At
each time point, patients were queried regarding all concur-
rent medications, with particular attention to antiplatelet
therapy. To exclude potential bias for longer prescription of
DAPT because of early ischemic events and/or repeat
revascularization, patients with adverse events occurring
within 6 months of the index revascularization, including
thrombotic events, major bleeding, and any repeat revascu-
larization, were excluded from this analysis population.
Patient groups were then categorized by DAPT adherence
according to the most recent report of compliance with
aspirin and thienopyridine therapy. For patients to qualify
for the 12- and 24-month DAPT cohorts, they must
also have reported aspirin and thienopyridine compliance at
6-month surveillance. Planned comparisons therefore in-
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1121cluded “6 months on/12 months off” (meaning, on DAPT
at 6 months but not at 12 months) versus “12 months” (on
DAPT at 6 and 12 months), and “6 months on/24 months
off” (on DAPT at 6 but not at 24 months) versus “24
months” (on DAPT at 6 and 24 months).
Study endpoints and deﬁnitions. The primary objective of
this pooled analysis of patients treated with ZES was to
evaluate late-term safety outcomes relative to the duration
of DAPT adherence. Clinical safety outcomes included
all-cause and cardiac death, MI, stroke, and ST (per
Academic Research Consortium criteria [20]) annually
through 3-year follow-up. Cardiac death was considered as
any fatal event not attributable to a noncardiac cause.
Myocardial infarction was defined as a creatine kinase (CK)
elevation2 times above the upper limit of normal with any
associated elevation in the CK myocardial band or the
development of new pathological Q waves in at least 2
contiguous electrocardiographic leads. Stroke was qualified
as any focal neurological deficit attributed to cerebrovascular
hemorrhage, embolism, thrombosis, or rupturing aneurysm
that persisted 24 h. Major bleeding was defined as any
hemorrhagic event that required blood product transfusion.
All clinical endpoints were adjudicated by an independent
clinical events committee, and except for the ENDEAVOR II
continued access registry, reviewers were blinded to the
patient’s treatment assignment.
Statistical methods. From the individual trials, patients
were analyzed for all safety endpoints based on the intent-
to-treat principle. Baseline characteristics of study patients
were summarized in terms of frequencies and percentages
for categorical variables and by means with standard devi-
ations for continuous variables. Categorical variables were
compared by Fisher exact test. Continuous variables were
compared by the 2-sample t test. The Cochran-Armitage
Figure 1. DAPT Use in Patients Treated With ZES Through 3 Years
Compliance with dual antiplatelet therapy (DAPT) among patients treated w
population (n  2,032, red bars) and the study population censored for 6-m
(n  1,414, blue bars).test was conducted to test the presence of an associationbetween DAPT usage and the different ENDEAVOR trials
(the time of enrollment is ordered with different trials).
Clinical outcomes were compared after adjusting p values
using propensity scores calculated from age, sex, trial, study
year, diabetes, hypertension, history of smoking, hyperlip-
idemia, prior MI, angina class III/IV, prior percutaneous
coronary intervention, prior coronary artery bypass graft
surgery, target vessel location, type B2/C lesion, reference
vessel diameter, lesion length, total stent length, number of
diseased vessels, and left ventricular ejection fraction.
Clinical predictors of thrombotic vascular events, includ-
ing death, MI, stroke, and ST were identified using multi-
variable logistic regression. A p value of 0.05 was established
as the level of statistical significance for all tests. All analyses
were performed using SAS software (version 8.2, SAS
Institute, Cary, North Carolina).
Results
As part of 5 registration trials involving 2,032 patients
undergoing percutaneous revascularization with ZES, treat-
ment with aspirin and thienopyridine therapy ranged from
95.4% at 30 days to 24.6% at 3 years (Fig. 1). Among these
patients, 1,414 patients were identified free of major ischemic
and bleeding events in the initial 6 months following
revascularization, of which 1,375 had complete records of
antiplatelet therapy use at 12 months, and 1,342 at 24
months (Fig. 1). Among these trials, DAPT duration was
significantly higher at 12 and 24 months relative to the time
of study enrollment (p  0.0001). Specifically, an extended
duration of DAPT was common with more recent trials, a
finding consistent with the introduction of treatment guide-
lines (2,7) and evolving practice patterns.
For the patients with 6-month event-free survival in-
otarolimus-eluting stents (ZES) through 3-year follow-up for the overall
ajor adverse events and with complete detail regarding DAPT complianceith z
onth mcluded in this study population, overall composite rates of
onary in
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1122death, MI, and stroke were 2.1% and 3.9% at 2 and 3 years,
respectively. The interval incidence of definite/probable ST
evaluated from 6 months was 0.2% at 2 years and 0.2% at 3
years.
Among patients excluded due an ischemic or bleeding
event before 6 months (n  618), baseline demographics
varied inconsistently with those patients (n  1,414) not
experiencing an event. In the former group, prior MI and
class III/IV angina classification were more common,
whereas diabetes and smoking history were more prevalent
among patients event-free at 6 months. However, adherence to
DAPT at all measured time points (30 days through 3 years)
was significantly (p 0.001) lower among patients experienc-
ing an event within 6 months of index revascularization.
Despite such differences, risk-adjusted outcomes of death, MI,
stroke, or ST did not statistically differ beyond 6 months and
over the studied 3-year interval.
Late-term outcomes were examined according to the last
reported follow-up interval of compliance with both aspirin
and clopidogrel: 6 months (n 716), 12 months (n 659),
and 24 months (n  516). To enable a balanced compari-
son, patients on DAPT at 24 months were evaluated against
those reporting 6-month DAPT compliance but not at 24
Table 1. Baseline Clinical and Angiographic Characteristics According to D
and Event-Free Survival
Off at 12 Months
(n  716)
On at 12 Mon
(n  659)
Age, yrs 62.4 10.6 63.2 10.8
Male 69.6 71.9
Diabetes mellitus 27.7 27.8
Hypertension 73.6 75.4
History of smoking 52.3 51.1
Hyperlipidemia 80.5 83.1
Prior myocardial infarction 25.4 26.8
Angina class III/IV 44.7 38.9
Prior PCI 23.1 32.0
Prior CABG 5.7 8.8
Target vessel
Left anterior descending artery 45.9 40.6
Left circumﬂex artery 24.0 25.8
Right coronary artery 30.2 33.6
Type B2/C lesions 72.2 70.8
Reference vessel diameter, mm 2.72 0.48 2.71 0.47
Lesion length, mm 14.23 5.85 14.14 6.41
Total stent length, mm 23.17 7.21 22.13 7.44
Number of diseased vessels, %
1 64.1 52.5
2 24.2 29.6
3 11.7 17.9
Left ventricular ejection fraction, % 57.95 10.06 59.15 10.5
Values are mean SD or %.
CABG coronary artery bypass graft; DAPT dual antiplatelet therapy; PCI percutaneous cormonths (n  826 accounting for more complete ascertain-ment of data at 24 months). Compared with patients treated
with DAPT 12 months (i.e., both 12- and 24-month
groups), those in the 6-month cohort had less diabetes,
hypertension, smoking history, and prior coronary revascu-
larization (Table 1). Multivessel coronary disease was also
more prevalent in the extended (12 months) DAPT
groups. In contrast, a prior history of MI and revasculariza-
tion of the left anterior descending coronary artery as the
target vessel were more frequent among patients in the
6-month group.
Following adjustment for clinical and angiographic risk,
no significant differences were observed relative to DAPT
duration regarding adverse ischemic events at 2 or 3 years
(Table 2). Individual and composite rates of cardiovascular
death, MI, and ST did not significantly differ between
comparator groups. At 2 years, for example, the combined
event rate of death, MI, and stroke was 1.8% for the 6
months on/12 month off cohort and 2.3% for the 12
months group (p 0.66; hazard ratio: 1.25, 95% confidence
interval: 0.60 to 2.63); at 3 years, death, MI, or stroke
occurred in 3.9% for both the 6 months on/12 months off
and 12 months groups, respectively (p  0.79; hazard
ratio: 0.96, 95% confidence interval: 0.56, 1.67). Similarly,
Duration for Patients With 6-Month DAPT Compliance
p Value
Off at 24 Months
(n  826)
On at 24 Months
(n  516) p Value
0.16 62.2 10.3 63.6 11.0 0.03
0.34 71.4 69.4 0.42
1.00 26.3 29.7 0.19
0.46 71.4 79.5 0.001
0.66 48.7 56.2 0.008
0.23 81.7 81.4 0.89
0.54 26.3 24.5 0.52
0.03 42.9 39.7 0.27
0.001 24.8 30.2 0.03
0.03 5.9 8.9 0.05
0.05 46.8 40.8 0.13
0.45 21.1 28.2 0.02
0.18 32.2 31.1 0.55
0.59 73.9 73.0 0.35
0.69 2.70 0.47 2.74 0.48 0.26
0.79 14.22 6.05 13.97 6.24 0.35
0.43 22.84 6.92 21.59 7.41 0.005
0.001 61.8 54.1 0.004
0.02 24.1 28.5 0.16
0.001 14.1 17.4 0.02
0.04 60.95 10.42 58.13 10.40 0.18
tervention.APT
ths
8at 2 and 3 years, the composite of death, MI, or stroke did
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1123not statistically differ between the 6 months on/24 months
off and 24 months group comparisons (Table 2). Major
bleeding events beyond 6 months of revascularization were
not observed at any follow-up interval.
Logistic regression was applied using clinical and angio-
graphic variables to identify predictors of late ischemic
events. In multivariable analysis, among selected characteristics
ssociated with higher risk, none were significantly predictive
f 2- or 3-year events. In particular, duration of thienopyridine
12 months was not associated with a significantly greater
ikelihood of individual or combined outcomes of late-term
eath, MI, Academic Research Consortium definite/
robable ST, or stroke (Tables 3 and 4).
iscussion
Although prescription of a thienopyridine and aspirin for at
Table 2. Risk-Adjusted Clinical Outcomes According to Duration of DAPT
2 Yrs
Off at 12 Months
(n  711)
On at 12
(n 
Death 1.3 (9) 1.2 (
Cardiac death 0.6 (4) 0.3 (
MI 0.1 (1) 0.8 (
Q-wave 0.1 (1) 0
Non–Q-wave 0 0.8 (
Stroke 0.6 (4) 0.3 (
ST 0.7 (5) 0.2 (
Deﬁnite 0.3 (2) 0
Deﬁnite/probable 0.3 (2) 0
Probable 0 0
Possible 0.4 (3) 0.2 (
Major bleeding 0 0
Death/MI/stroke 1.8 (13) 2.3 (
Death/MI/stroke/ARC deﬁnite/probable ST 2.0 (14) 2.3 (
3 Yrs
Off at 12 Months
(n  700)
On at 12
(n 
Death 2.7 (19) 2.2 (
Cardiac death 1.0 (7) 0.3 (
MI 0.3 (2) 1.1 (
Q-wave 0.1 (1) 0
Non–Q-wave 0.1 (1) 1.1 (
Stroke 1.0 (7) 0.8 (
ST 0.9 (6) 0.3 (
Deﬁnite 0.3 (2) 0
Deﬁnite/probable 0.3 (2) 0
Probable 0 0
Possible 0.7 (5) 0.3 (
Major bleeding 0 0
Death/MI/stroke 3.9 (27) 3.9 (
Death/MI/stroke/ARC deﬁnite/probable ST 4.0 (28) 3.9 (
Values are % (n).
ARC Academic Research Consortium; DAPT dual antiplatelet therapy; MImyocardial infarleast 12 months following DES revascularization has be-come commonplace, there is insufficient evidence to inform
practice regarding the “optimal” duration of DAPT (14), in
particular, the length of treatment that is most effective in
decreasing vascular thrombotic events balanced by risk of
potentially life-threatening bleeding complications. More-
over, despite the recommendation for continued DAPT
that in some circumstances has been advocated as indefinite
treatment following DES placement (21), patient compli-
ance and the frequent yet unanticipated clinical need for
interruption of thienopyridine therapy challenge the possi-
ble benefit perceived by intention to treat. In particular, the
safety of thienopyridine discontinuation following even
several months of DAPT is a common yet unsettling
circumstance. Considering these ongoing uncertainties
related to the risks and benefits of long-term DAPT
following DES treatment, and the low rates of cardiac
hs
p Value
Off at 24 Months
(n  826)
On at 24 Months
(n  516) p Value
0.58 0.5 (4) 0.6 (3) 0.82
0.19 0 0.6 (3) 0.09
0.14 0.1 (1) 1.0 (5) 0.13
0.32 0 0.2 (1) 0.32
0.03 0.1 (1) 0.8 (4) 0.23
0.30 0.6 (5) 0.2 (1) 0.23
0.08 0.1 (1) 0.4 (2) 0.21
0.19 0.1 (1) 0.2 (1) 0.43
0.19 0.1 (1) 0.2 (1) 0.43
— 0 0 —
0.19 0 0.2 (1) 0.32
— 0 0 —
0.96 1.2 (10) 1.6 (8) 0.73
0.78 1.3 (11) 1.6 (8) 0.69
hs
p Value
Off at 24 Months
(n  816)
On at 24 Months
(n  511) p Value
0.48 1.6 (13) 1.6 (8) 0.79
0.05 0.4 (3) 0.6 (3) 0.53
0.19 0.4 (3) 1.2 (6) 0.21
0.32 0 0.2 (1) 0.32
0.08 0.4 (3) 1.0 (5) 0.33
0.42 1.2 (10) 0.4 (2) 0.10
0.13 0.4 (3) 0.4 (2) 0.96
0.19 0.1 (1) 0.2 (1) 0.44
0.19 0.1 (1) 0.2 (1) 0.44
— 0 0 —
0.27 0.2 (2) 0.2 (1) 0.59
— 0 0 —
0.75 3.2 (26) 2.7 (14) 0.42
0.70 3.3 (27) 2.7 (14) 0.41
T stent thrombosis.Mont
654)
8)
2)
5)
5)
2)
1)
1)
15)
15)
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14)
2)
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5)
2)
2)
25)
25)death, MI, and ST observed with ZES in the context of
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1124key clinical trials, there is a rationale to evaluate clinical
outcomes among patients treated with ZES and across
variable time courses of DAPT. In this analysis limited to
clinically stable patients undergoing elective percutaneous
revascularization with ZES and censored for early (6
onths) adverse events, late (3 years) safety outcomes
ere independent of DAPT treatment durations ranging
rom 6 months to 2 years.
Recognition that adherence to thienopyridine therapy
ollowing DES treatment is highly variable also emphasizes
need to define the relationship between clinical outcome
nd antiplatelet therapy duration. In part, as a result of
nadequate patient education, cost, or clinical events that
ecessitate at least temporary interruption of DAPT (2),
iscontinuation of thienopyridine therapy following DES
lacement in contemporary practice is common, ranging
rom 14% at 30 days following revascularization to more
han 80% beyond 1 year (22). Unlike earlier generation
Table 3. Predictive Value of Selected Clinical Charac
6 Months DAPT Versus >12 Months DAPT
Predictors of Safety Outcomes at a 3-Yr Simple Logistic
Death
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 12 months)
Cardiac death
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 12 months)
MI
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 12 months)
ARC deﬁnite/probable ST
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 12 months)
Stroke
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 12 months)
Death/MI/Stroke
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 12 months)
CI confidence interval; other abbreviations as in Table 2.ES programs, compliance with both aspirin and thien-opyridine therapy has been examined in studies with
ZES. In key clinical trials evaluating the safety and
efficacy of the Endeavor stent, DAPT was recommended
for a minimum of 3 months post-procedure, followed by
indefinite treatment with aspirin, and longer duration of
treatment with clopidogrel was prescribed according to
the treating physician’s discretion. Extended duration of
DAPT for at least 1 year was especially more common
with recent trials, but consistent with prior studies, an
attrition in the compliance rate with DAPT was observed
with time (Fig. 1). Among the 2,032 patients initially
included in the present study, although 76% of patients
were taking aspirin and thienopyridine therapy at 6
months following initial revascularization, only 40%,
32%, and 25% reported adherence at 1, 2, and 3 years,
respectively. Although the prescribing patterns relative to
duration of DAPT differed according to the time of trial
conduct, studies performed earlier were associated with
ics for 3-Year Safety Outcomes,
ssion Odds Ratio (95% CI) p Value
0.99 (0.46–2.14) 0.97
0.98 (0.92–1.03) 0.37
1.16 (0.56–2.39) 0.69
1.26 (0.63–2.54) 0.51
0.75 (0.16–3.63) 0.72
1.01 (0.92–1.10) 0.91
1.94 (0.52–7.20) 0.32
3.26 (0.68–15.76) 0.14
0.75 (0.16–3.63) 0.72
1.01 (0.92–1.10) 0.87
1.76 (0.47–6.60) 0.40
0.26 (0.05–1.27) 0.10
2.64 (0.17–42.29) 0.49
1.03 (0.87–1.21) 0.73
41.56 (2.50–689.59) 0.001
— 0.94
1.32 (0.40–4.41) 0.65
1.00 (0.92–1.08) 0.96
0.41 (0.11–4.50) 0.18
1.30 (0.41–4.11) 0.66
0.97 (0.52–1.81) 0.92
0.99 (0.95–1.03) 0.66
1.02 (0.57–1.83) 0.95
1.00 (0.57–1.74) 1.00terist
Regreshorter DAPT durations, and yet were also those with
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 0 , 2 0 1 1 Kandzari et al.
O C T O B E R 2 0 1 1 : 1 1 1 9 – 2 8 Antiplatelet Therapy and Zotarolimus-Eluting Stent
1125the longest duration of follow-up and did not indicate an
increase in late adverse outcomes.
Although observational studies have consistently associ-
ated premature discontinuation of DAPT with a higher risk
of ST (10–13), others have demonstrated that long-term
continuance may be associated with reductions in death and
MI, yet may not influence ST events (3,8,9). Still other
reports have documented late ST with sirolimus and pacli-
taxel DES in the presence of DAPT (23,24). It may be that
in those studies in which long-term combination antiplate-
let therapy appears beneficial, the treatment effect may be
mediated by a reduction in events unrelated to the target
lesion, as the likelihood of progression of atherosclerosis
exceeds the absolute risk of ST. In addition, although
12-month therapy with clopidogrel and aspirin has been
associated with benefit in patients with acute coronary
syndromes and in percutaneous coronary intervention, the
late-term reduction in death and MI were principally driven
Table 4. Predictive Value of Selected Clinical Charac
6 Months DAPT Versus >24 Months DAPT
Predictors of Safety Outcomes at a 3-Yr Simple Logistic
Death
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 24 months)
Cardiac death
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 24 months)
MI
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 24 months)
ARC deﬁnite/probable ST
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 24 months)
Stroke
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 24 months)
Death/MI/Stroke
History of diabetes
Total stent length
Pre-procedure reference vessel diameter (per mm)
DAPT (6 months vs. 24 months)
Abbreviations as in Tables 2 and 3.by reductions in risk of MI within the initial 30 days(7,8,25). By exclusion of patients experiencing early (6
months) events and in part related to a consistently low risk
of late adverse outcomes across the ZES studies, pro-
longed DAPT beyond a minimum of 6 months did not
appear to modify the risk of late or very late ST. Since
late adverse event rates are infrequent in this selected
patient population, extending the DAPT duration be-
yond 6 months in such patients treated with ZES may
not offer incremental benefit.
Whether outcomes may be generalized to broader risk
populations and across other stent types (both bare metal
and drug eluting) with varied durations of DAPT and is also
uncertain. Notably, when similar analyses were applied to a
much smaller group of patients treated with sirolimus- and
paclitaxel-eluting stents in 2 comparative studies with ZES,
adverse events were similar, if not lower, among patients
reporting adherence at 6 or 12 months, but not longer
durations (Table 5). Considering these smaller patient
ics for 3-Year Safety Outcomes,
ssion Odds Ratio (95% CI) p Value
1.63 (0.67–3.97) 0.28
0.96 (0.90–1.04) 0.32
1.24 (0.50–3.05) 0.64
1.02 (0.42–2.47) 0.97
1.32 (0.24–7.21) 0.75
1.03 (0.94–1.13) 0.55
3.59 (0.77–16.77) 0.11
0.63 (0.13–3.11) 0.57
0.75 (0.16–3.62) 0.72
1.01 (0.92–1.10) 0.87
1.73 (0.46–6.55) 0.42
0.31 (0.08–1.25) 0.10
2.63 (0.16–42.16) 0.49
1.03 (0.87–1.21) 0.73
41.49 (2.51–686.40) 0.009
0.63 (0.04–10.03) 0.74
1.32 (0.39–4.40) 0.66
1.00 (0.92–1.08) 0.96
0.39 (0.11–1.46) 0.16
3.16 (0.69–14.46) 0.14
1.27 (0.65–2.50) 0.48
0.99 (0.95–1.04) 0.69
1.00 (0.51–1.96) 0.799
1.17 (0.60–2.26) 0.64terist
Regrecohorts, such findings should be cautiously interpreted.
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1126However, the findings in this study are at least consistent
with an increasing number of other trials evaluating the role
in extending aspirin and thienopyridine treatment to reduce
late-term ST in less selected patient populations (22,26–31). In
nearly all trials, ST is significantly more common with
thienopyridine discontinuation before 6 months following
DES revascularization, although cessation (vs. continua-
tion) beyond 6 months did not affect later events through
variable late-term follow-up (22,26–29). Other surveys have
indicated that DAPT therapy beyond 6 months may be
more related to prevention of vascular thrombotic events
occurring independently of the stent type or target lesion
territory (32). To this point, although occurrence of stroke
was infrequent in all studied groups, the absolute reduction
was directionally lower among patients with DAPT adher-
ence 12 months. Nonetheless, these findings are consistent
with other studies reporting no significant reduction in stroke
with extended DAPT (9,31,33). In the only prospective,
randomized trial to date comparing 1- versus 2-year DAPT in
patients without prior events for at least 1 year after DES
treatment, long-term DAPT did not improve rates of death,
MI, stroke, or ST (31).
Until further randomized trials may define the optimal
duration of DAPT, the incremental risk of bleeding com-
plications with DAPT must be weighed against potential
reductions in ST. Among prior studies examining the
influence of long-term DAPT following DES placement,
few have quantified potential reductions in adverse events
with increased bleeding risk. Despite annual surveillance in
the present study, however, no major bleeding events were
identified in any DAPT group more than 6 months beyond
revascularization. Although this finding lessens the relative
risk to benefit of continued DAPT, it also implies that
reasons for late clopidogrel discontinuation were not directly
related to severe hemorrhagic events. The absence of major
bleeding events beyond 6 months also adds to already
inconsistent results across prior trials evaluating extended
duration of aspirin and thienopyridine treatment. Indeed, in
Table 5. Risk-Adjusted 3-Year Clinical Outcomes According to Duration of
Sirolimus- and Paclitaxel-Eluting Stents in ENDEAVOR Trials
Off at 12 Months
(n  297)
On at 12
(n 
Death 2.7 5.
Cardiac death 0.7 3.
Myocardial infarction 1.7 2.
Deﬁnite/probable stent thrombosis 0.7 1.
Stroke 0.7 0.
Death/MI/stroke/ARC deﬁnite/probable ST 4.8 8.
Major bleeding 0.7 0
Values are %.
Abbreviations as in Table 2.trials evaluating extended treatment with DAPT rangingfrom 9 months to 2 years and independent of stent revas-
cularization, major bleeding rates have ranged from 2% to
4% (25,33,34), and by indirect comparison, well exceed
he observed frequency of ST in this analysis. Alternatively,
he DES-LATE (Optimal Duration of Clopidogrel Ther-
py After Drug-Eluting Stent Implantation to Reduce Late
oronary Arterial Thrombotic Events) randomized trial
eported a 2-year major bleeding rate of only 0.2% for
atients treated with long-term DAPT who were initially
vent-free for a minimum of 12 months (31). Such disparity
ay in part reflect differences in trial design as studies that
mit patients with early bleeding events (and subsequent
hienopyridine discontinuation) may represent a selection
ias and underestimate overall bleeding risk.
Study limitations. In the absence of randomization, a limi-
tation to this analysis is that despite risk adjustment, the
possibility that measured or unmeasured confounders may
have affected DAPT prescription or the study results cannot
be excluded. Extended prescription of DAPT was physician
and patient dependent and therefore not pre-specified.
However, the purpose of this analysis was not to evaluate
outcomes according to prospectively defined DAPT dura-
tions, but instead to examine late safety outcomes following
discontinuation at varied time intervals. Although this
analysis represents the largest DES population in which
outcomes relative to DAPT have been examined through
3-year follow-up, the overall low ischemic adverse event and
bleeding rates observed with ZES limit the statistical power
for comparison, as well as trial heterogeneity, and therefore
these results should be considered hypothesis-generating
rather than definitive. Further study in a prospective,
adequately powered (and randomized) trial of antiplatelet
therapy duration will be required to confirm this retrospec-
tive observation. In addition, these findings were observed
among patients undergoing elective percutaneous revascu-
larization with relatively simple to moderate lesion complex-
ity, and thus the results cannot be extended to high clinical
risk and complex lesion patient populations. In prior studies
for 6-Month Event-Free Patients Treated With
hs
p Value
Off at 24 Months
(n  220)
On at 24 Months
(n  438) p Value
0.08 3.2 3.2 0.95
0.01 0.5 2.1 0.07
0.67 1.4 2.3 0.31
0.26 0.9 1.4 0.52
0.42 0.5 0.7 0.97
0.10 5.0 6.2 0.52
0.16 0.5 0.2 0.87DAPT
Mont
380)
1
0
4
9
5
1documenting late ST with DES (10–12,23,26), increasing
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1127patient and lesion complexity also designated significant
risk. Information regarding antiplatelet therapy interrup-
tions and the rationale for cessation, resuming, or extending
prescription of DAPT was not ascertained, although pa-
tients were censored for adverse bleeding and ischemic
events before 6 months (including repeat revascularization)
to mitigate selection bias. Nevertheless, adverse events
related to repeat revascularization (and the need for ex-
tended DAPT) during the follow-up period beyond 6
months may have also confounded the study results; how-
ever, interim rates of target (and nontarget) vessel revascu-
larization were low, and exclusion of such patients from the
analysis does not alter the conclusions.
Conclusions
Following coronary revascularization with DES, the appro-
priate duration of aspirin and thienopyridine therapy re-
mains undefined. Studies demonstrating disparate results
regarding the impact of DAPT to reduce death and MI (but
not late and very late ST), and the empirical recommenda-
tion for extended therapy have raised questions as to
whether the optimal treatment regimen may be 1 year or
instead perhaps indefinitely. It is also uncertain whether any
benefit of DAPT to reduce the late-term ST risk is shared
equally among DES types, given that their risk of very late
ST may differ (35–37). Among selected patients treated
with ZES, long-term ischemic events do not statistically
differ among patients treated with 6 months (but 12
months) of DAPT compared with 12-month treatment.
In particular, extended DAPT beyond 6 months was not
associated with reductions in cardiovascular death, MI, or
ST. These findings merit further, definitive investigation
regarding the “optimal” duration of DAPT to characterize
the balance of risk and benefit in addition to whether
DAPT requirements differ according to DES type.
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